A Study of Naltrexone SR/Bupropion SR and Placebo in Obese Subjects Participating in a Behavior Modification Program - Full Text View

Sponsored by:	Orexigen Therapeutics, Inc
Information provided by:	Orexigen Therapeutics, Inc
ClinicalTrials.gov Identifier:	NCT00456521

Purpose

The purpose of this study is to determine whether a combination of 2 drugs is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program than with group lifestyle modification alone.

Condition	Intervention	Phase
Obesity	Drug: naltrexone SR/bupropionSR combination Behavioral: Group lifestyle modification counseling	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Phase 3 Study Comparing the Safety and Efficacy of Naltrexone SR/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program

Resource links provided by NLM:

MedlinePlus related topics: Obesity

Drug Information available for: Naltrexone Naltrexone hydrochloride Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by Orexigen Therapeutics, Inc:

Primary Outcome Measures:

Change in percentage of total body weight lost [ Time Frame: Baseline to week 56 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Effect on selected obesity-associated cardiovascular risk factors, including serum triglycerides, HDL and LDL cholesterol, waist circumference, glucose and insulin levels. [ Time Frame: Baseline to week 56 ] [ Designated as safety issue: No ]
Proportion of subjects who lose at least 5% and 10% of their baseline body weight [ Time Frame: Baseline to week 56 ] [ Designated as safety issue: No ]

Enrollment:	793
Study Start Date:	April 2007
Study Completion Date:	December 2008
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Group 1: Active Comparator	Drug: naltrexone SR/bupropionSR combination naltrexone SR 32 mg/bupropion SR 360 mg per day Behavioral: Group lifestyle modification counseling Group lifestyle modification counseling
Group 2: Placebo Comparator	Behavioral: Group lifestyle modification counseling Group lifestyle modification counseling

Detailed Description:

The combination of group lifestyle modification counseling and pharmacotherapy has recently been shown to result in nearly twice the average weight loss at one year (12.1 kg) as pharmacotherapy alone (sibutramine, 5.0 kg) or lifestyle modification counseling alone (6.7 kg. Combining pharmacotherapy with a comprehensive program of diet, exercise and group lifestyle modification counseling may provide the best weight loss regimen. This study will evaluate weight loss in subjects participating in such a comprehensive program who receive a combination of naltrexone SR and bupropion SR or placebo.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Female and male subjects, 18 to 65 years of age
Have body mass index (BMI) between 30 and 45kg/m2 for subjects with uncomplicated obesity, and 27 and 45kg/m2 for subjects with obesity and controlled hypertension and/or dyslipidemia
Non-smoker and no use of tobacco or nicotine products for at least 6 months
Normotensive(< 140/90 mm Hg), some anti-hypertensive medications are allowed
LDL cholesterol < 190 mg/dL and triglycerides < 400 mg/dL
Women of child bearing potential must have negative serum pregnancy, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after stopping study drug

Exclusion Criteria:

Obesity of known endocrine origin such as untreated hypothyroidism or Polycystic Ovary Syndrome
Serious medical condition
Serious psychiatric illness
Type I or Type II diabetes mellitus
Need of medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months
On prohibited concomitant medication
History of surgical or device (e.g. lap band) intervention for obesity
History of seizures or predisposition to seizures

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00456521

Locations

United States, California
UCSD: Dept of Family & Preventive Medicine
La Jolla, California, United States, 92093
United States, Colorado
Center for Human Nutrition, University of Colorado Health Services Center
Denver, Colorado, United States, 80220
United States, Florida
University of Florida
Gainesville, Florida, United States, 32611
United States, Missouri
Washington Univ. Center for Human Nutrition
St. Louis, Missouri, United States, 63110
United States, New York
NY Obesity Research Center
New York, New York, United States, 10025
United States, Pennsylvania
Center for Obesity Research and Education
Philadelphia, Pennsylvania, United States, 19140
Center for Weight & Eating Disorder
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
MUSC Weight Mnagement Center
Charleston, South Carolina, United States, 29425

Sponsors and Collaborators

Orexigen Therapeutics, Inc

Investigators

Principal Investigator:

Frank Greenway, MD

Pennington Biomedical Research Center, Baton Rouge, Louisiana

More Information

No publications provided

Responsible Party:	Orexigen Therapeutics, Inc ( Eduardo Dunayevich, MD )
Study ID Numbers:	NB-302
Study First Received:	April 3, 2007
Last Updated:	January 5, 2009
ClinicalTrials.gov Identifier:	NCT00456521 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Orexigen Therapeutics, Inc:

Obesity
Behavior Modification

Study placed in the following topic categories:

Dopamine Uptake Inhibitors
Obesity
Neurotransmitter Agents
Narcotic Antagonists
Psychotropic Drugs
Overweight
Narcotics
Body Weight
Signs and Symptoms

Dopamine
Bupropion
Naltrexone
Nutrition Disorders
Dopamine Agents
Overnutrition
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Obesity
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Narcotic Antagonists
Physiological Effects of Drugs
Psychotropic Drugs
Overweight
Pharmacologic Actions
Body Weight
Signs and Symptoms

Sensory System Agents
Therapeutic Uses
Naltrexone
Bupropion
Nutrition Disorders
Dopamine Agents
Overnutrition
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on September 02, 2009